DR. DAVID P MONTESANTI, MD
Medical Practice at Elmwood Ave, Buffalo, NY
License number
New York 215803
Category
Medical Practice
Type
Ophthalmology
Address
Address
932 Elmwood Ave, Buffalo, NY 14222
Phone
(716) 884-0880
(716) 884-0811 (Fax)
(716) 631-8888
(716) 631-3803 (Fax)
(716) 884-0811 (Fax)
(716) 631-8888
(716) 631-3803 (Fax)
Personal information
See more information about DAVID P MONTESANTI at radaris.comName
Address
Phone
4128 Buckingham Dr, Schenectady, NY 12304
6300 Crosswinds Ct, East Amherst, NY 14051
4128 Buckingham Dr, Schenectady, NY 12304
23 Argyle, Amherst, NY 14226
1608 Sweet Home Rd, Buffalo, NY 14228
Organization information
See more information about DAVID P MONTESANTI at bizstanding.comEye Care & Vision Associate - David P Montesanti MD
932 Elmwood Ave, Buffalo, NY 14222
Categories:
Ophthalmology Physicians & Surgeons, Physicians & Surgeons
Site:
Phone:
(716) 884-0880 (Phone)
Specialties:
Diabetes, Glaucoma
Products:
Cataract Surgery, LASIK, Plastic Surgery
Professional information
Dr. David P Montesanti, Niagara Falls NY - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
6917 Plaza Dr, Niagara Falls 14304
(716) 297-1700 (Phone)
(716) 297-1700 (Phone)
Certifications:
Ophthalmology, 2003
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
6917 Plaza Dr, Niagara Falls 14304
Mercy Hospital
565 Abbott Rd, Buffalo 14220
Mount Saint Mary's Hospital and Health Center
5300 Military Rd, Lewiston 14092
Niagara Falls Memorial Medical Center
621 10Th St, Niagara Falls 14302
Mercy Hospital
565 Abbott Rd, Buffalo 14220
Mount Saint Mary's Hospital and Health Center
5300 Military Rd, Lewiston 14092
Niagara Falls Memorial Medical Center
621 10Th St, Niagara Falls 14302
Education:
Medical School
Suny Downstate Medical Center College Of Medicine
Graduated: 1998
Suny Buffalo Grad Med Dent
Suny Downstate Medical Center College Of Medicine
Graduated: 1998
Suny Buffalo Grad Med Dent
David P Montesanti, Niagara Falls NY
Specialties:
Ophthalmology
Work:
Eye Care & Vision Associates
6917 Plaza Dr, Niagara Falls, NY 14304 Williamsville Office
1 Hopkins Rd, Buffalo, NY 14221 Downtown Buffalo Office
932 Elmwood Ave, Buffalo, NY 14222
6917 Plaza Dr, Niagara Falls, NY 14304 Williamsville Office
1 Hopkins Rd, Buffalo, NY 14221 Downtown Buffalo Office
932 Elmwood Ave, Buffalo, NY 14222
Education:
State University of New York at Buffalo (1998)
David Paul Montesanti, Buffalo NY
Specialties:
Ophthalmologist
Address:
1 Hopkins Rd, Buffalo, NY 14221
Education:
Doctor of Medicine
Board certifications:
American Board of Ophthalmology Certification in Ophthalmology
Methods For Identifying Or Diagnosing Carcinoma Cells With Metastatic Potential Based On The Measurement Of Lymphoid Genes Or Their Products In Carcinoma Cells
US Patent:
6790604, Sep 14, 2004
Filed:
May 12, 1998
Appl. No.:
09/110376
Inventors:
Stefan A. Cohen - East Amherst NY 14051
Untae Kim - Snyder NY 14226
David P. Montesanti - West Amherst NY 14228
Untae Kim - Snyder NY 14226
David P. Montesanti - West Amherst NY 14228
International Classification:
C12Q 100
US Classification:
435 4, 435 71, 435 6, 436 64
Abstract:
A method of predicting the lymphotropic metastatic potential of a solid non-lymphoid tumor. The percentage of cells of each of a plurality of representative samples of the tumor which express lymphoid gene products is determined. The metastatic potential is predicted to be low when no tumor cells in all of the samples are detected to express lymphoid gene products. The metastatic potential is predicted to be high when a high percentage of tumor cells in at least one of the samples are detected to express lymphoid gene products. A solid non-lymphoid tumor is treated by systemically administering a substance comprising a therapeutically effective amount of a molecule linked to a toxin, radionuclide, or chemotherapeutic agent and having binding specificity for a tumor specific lymphoid gene product idiotype. The lymphotropic metastatic potential of a primary solid non-lymphoid tumor is predicted by sub-cutaneously injecting cells from the tumor into at least one anti-AsGMI-treated nude mouse and examining the mouse for tumors at sites other than the site of injection.